Previous studies (85–89) have demonstrated that CSNK2A1 promotes tumorigenesis by enhancing several oncogenic signaling pathways in various malignancies, including breast cancer, lung cancer, kidney cancer, colorectal cancer, and prostate cancer. This evidence concerns the gene CSNK2A1 and prostate cancer.